

# Phase 1/2 Open-Label Dose-Escalation Study to Evaluate Safety of a Single Intravitreal Injection of RTx-021 in Patients With Stargardt Disease

NCT07439887

---

<b>Status</b>	RECRUITING
<b>Phase</b>	Phase 1, Phase 2
<b>Sponsor</b>	Ray Therapeutics, Inc.
<b>Enrollment</b>	18 participants

## Key Eligibility Criteria

---

### Inclusion (6)

- Male and female patients  $\geq$  16 years of age
  - Able to comply with the study visit schedule and all protocol assessments
  - Diagnosis of Stargardt Disease (genetic testing required)
  - Study eye and fellow eye Best Corrected Visual Acuity meeting study criteria
  - Presence of retinal ganglion cells and/or retinal nerve fiber layer on Spectral Domain Optical Coherence Tomography testing at Screening confirmed by central image reading center
- ... and 1 more (see full listing online)

### Exclusion (13)

- Participation in a clinical study (ocular or non-ocular) with an investigational drug, agent, or therapy in the past six months
  - Concurrent participation in another interventional clinical ocular study
  - Prior receipt of any gene therapy (ocular or other), retinal implant, or ocular cell therapy
  - Pre-existing eye conditions in either eye that would preclude the planned treatment or are significant enough to interfere with the interpretation of study endpoints or procedural complications
  - Known steroid responders if their intraocular pressure was not able to be managed effectively with topical pressure-lowering medications after prior use of steroid medications
- ... and 8 more (see full listing online)

## Locations (2 total)

---

RayTx Clinical Site, Bakersfield, California, United States  
RayTx Clinical Site, Bellaire, Texas, United States

---

<https://clinicaltrials.gov/study/NCT07439887>

DISCLAIMER: This document is for informational purposes only and does not constitute medical advice. Always consult your healthcare provider before enrolling in any clinical trial. Information may not be up to date — verify details at ClinicalTrials.gov. Generated by ClinicalTrialsFinder.org.